249 results
425
EX-10.2
LSTA
Lisata Therapeutics Inc
16 Nov 10
Business combination disclosure
12:00am
as it deems necessary to make any payments or distributions required under this Escrow Agreement. The Escrow Agent shall have no responsibility … .
EXECUTION VERSION
ARTICLE 2
DUTIES OF THE ESCROW AGENT
Section 2.1. Scope of Responsibility. Notwithstanding any provision to the contrary, the Escrow
CORRESP
LSTA
Lisata Therapeutics Inc
31 Aug 09
Correspondence with SEC
12:00am
making, both of which are exclusively the responsibility of the collection center (i.e., the responsibility of the physician or the medical practice … , NeoStem has the primary responsibility for determining the acceptability of the final collected stem cell product. Acceptability is dictated
8-K
EX-10.2
LSTA
Lisata Therapeutics Inc
16 Nov 10
NeoStem Announces Pricing of Concurrent
12:00am
as it deems necessary to make any payments or distributions required under this Escrow Agreement. The Escrow Agent shall have no responsibility … .
EXECUTION VERSION
ARTICLE 2
DUTIES OF THE ESCROW AGENT
Section 2.1. Scope of Responsibility. Notwithstanding any provision to the contrary, the Escrow
CORRESP
LSTA
Lisata Therapeutics Inc
10 May 10
Correspondence with SEC
12:00am
the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
the Company may not assert the staff comments
CORRESP
nkji7nsc3d28ehzcq
6 Oct 09
Correspondence with SEC
12:00am
CORRESP
hyeu7li
9 Jun 11
Correspondence with SEC
12:00am
CORRESP
i4rjovf7p1zyk4opj
10 May 10
Correspondence with SEC
12:00am
CORRESP
1zytlc
10 Feb 10
Correspondence with SEC
12:00am
CORRESP
0k64y7ujwx 9ofw6x
28 Sep 12
Correspondence with SEC
12:00am
CORRESP
x645af2nb0xacuz8bii
23 Apr 07
Correspondence with SEC
12:00am
CORRESP
7ebds k8w4vcsh3gt9y3
6 May 10
Correspondence with SEC
12:00am
8-K
EX-5.1
x3hz dm67e
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-5.1
1tb71
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
8-K
EX-99.1
qhh7ckxy
6 Mar 06
Departure of Directors or Principal Officers
12:00am
8-K
EX-99.1
gkr4l v64
8 Jul 14
NeoStem Appoints Steven M. Klosk to Board of Directors
12:00am
8-K
EX-10.1
3hnols19kyw7me8izd
14 Jul 11
Entry into a Material Definitive Agreement
12:00am